Ulas Babacan, Hasbek, and Seker examined the combined use of PSMA-PET imaging and traditional staging criteria, suggesting that PSMA-PET can enhance the prognostic accuracy for prostate cancer by integrating imaging parameters with established clinical models. The gene discussed is FOLH1; the disease is Familial prostate cancer.